Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation – A Systematic Review by Muensterman, Elena Tomaselli & Tisdale, James E.
DR JAMES E. TISDALE (Orcid ID : 0000-0002-2117-9463) 
Article type      : Special Article 
Predictive Analytics for Identification of Patients at Risk for QT Interval Prolongation – A 
Systematic Review 
Running Title: Prediction of QT Interval Prolongation 
Elena Tomaselli Muensterman* 
James E. Tisdale*† 
From the *Department of Pharmacy Practice, College of Pharmacy, Purdue University, 
Indianapolis, Indiana; †Division of Clinical Pharmacology, Department of Medicine, School of 
Medicine, Indiana University, Indianapolis, Indiana 
Address for correspondence: 
James E. Tisdale 
College of Pharmacy 
rdue University 
640 Eskenazi Avenue 
Indianapolis, IN 46202 
317-880-5418
___________________________________________________________________
This is the author's manuscript of the article published in final edited form as:
Muensterman, E. T., & Tisdale, J. E. (2018). Predictive Analytics for Identification of Patients at Risk for QT Interval 
Prolongation – A Systematic Review. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 
0(ja). https://doi.org/10.1002/phar.2146
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
317-880-0568 (fax) 
jtisdale@purdue.edu 
 
Key words:  QT interval; torsades de pointes; risk factors; predictive analytics; clinical decision 
support 
 
Conflict of Interest Statement 
 
Dr. Tomaselli Muensterman completed an internship at Takeda Pharmaceuticals U.S.A., Inc. 
during the summer of 2017. Dr. Tisdale is a volunteer member of the Advisory Board for the QT 
drugs list at CredibleMeds.org, which is discussed in this manuscript. The authors have no other 
conflicts of interest or industry relationships.  
 
ABSTRACT 
Prolongation of the heart rate-corrected QT (QTc) interval increases the risk for torsades de 
pointes (TdP), a potentially fatal arrhythmia. The likelihood of TdP is higher in patients with risk 
factors, which include female sex, older age, heart failure with reduced ejection fraction, 
hypokalemia, hypomagnesemia, concomitant administration of ≥ 2 QTc interval-prolonging 
medications, among others. Assessment and quantification of risk factors may facilitate 
prediction of patients at highest risk for developing QTc interval prolongation and TdP. 
Investigators have utilized the field of predictive analytics, which generates predictions using 
techniques including data mining, modeling, machine learning, and others, to develop methods 
of risk quantification and prediction of QTc interval prolongation. Predictive analytics have also 
been incorporated into clinical decision support (CDS) tools to alert clinicians regarding patients 
at increased risk of developing QTc interval prolongation. The objectives of this paper are to 
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assess the effectiveness of predictive analytics for identification of patients at risk of drug-
induced QTc interval prolongation, and to discuss the efficacy of incorporation of predictive 
analytics into CDS tools in clinical practice. A systematic review of English language articles 
(human subjects only) was performed, yielding 57 articles, with an additional 4 articles identified 
from other sources; a total of 10 articles were included in this review.  Risk scores for QTc 
interval prolongation have been developed in various patient populations including those in 
cardiac intensive care units (ICUs)  and in broader populations of hospitalized or health system 
patients. One group developed a risk score that includes information regarding genetic 
polymorphisms; this score significantly predicted TdP. Development of QTc interval 
prolongation risk prediction models and incorporation of these models into CDS tools reduces 
the risk of QTc interval prolongation in cardiac ICUs and identifies health-system patients at 
increased risk for mortality. The impact of these QTc interval prolongation predictive analytics 
on overall patient safety outcomes, such as TdP and sudden cardiac death relative to the cost of 
development and implementation, requires further study. 
 
Prolongation of the heart rate-corrected QT (QTc) interval on the electrocardiogram (ECG) 
increases the risk of the ventricular arrhythmia known as torsades de pointes (TdP), which can 
result in sudden cardiac death.1,2 The 99th percentile for the QTc interval is 480 milliseconds 
(ms) and 470 ms in adult women and men, respectively.3 Risk of TdP increases markedly when 
the QTc interval is < 500 ms.4-6 Each 10 ms increase in the QTc interval confers roughly a 6% 
increase in the risk of a cardiac event.7 The risk of TdP also increases when the QTc interval 
lengthens > 60 ms compared with the baseline value.8 
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 QTc interval prolongation may be inherited (congenital long QT syndrome [LQTS9]) or 
acquired, which is caused most commonly by medications. More than 150 drugs available in the 
United States prolong the QTc interval and have the potential to cause TdP.10 Drugs from a wide 
variety of therapeutic classes can prolong the QTc interval and cause TdP, including 
antimicrobials (macrolides, fluoroquinolones, azole antifungals), cardiovascular agents 
(antiarrhythmic drugs), antidepressants, antipsychotics, antineoplastic agents, methadone, and 
many others.10 QTc interval-prolonging drugs are prescribed frequently; nearly 23% of 
approximately 5 million outpatients filled at least one prescription for a QTc interval-prolonging 
medication during a one-year period.11  
 QTc interval prolongation occurs commonly. About 18% of patients admitted to cardiac 
intensive care units (ICUs) have a QTc interval > 500 ms on admission, and approximately 42% 
of those patients subsequently receive QTc interval-prolonging drugs while hospitalized.12 QTc 
interval prolongation develops in 24-52% of adult patient hospitalized in ICUs,13,14 and is present 
in as many as 35% of patients in emergency departments where the prevalence of markedly 
prolonged QTc interval (> 500 ms) is 1-8%15,16,17   QTc interval prolongation has been shown to 
be associated with increased risk for total and cardiovascular mortality.17 
 Numerous risk factors have been identified for QTc interval prolongation and TdP, and 
include older age, female sex, heart failure due to reduced ejection fraction, acute myocardial 
infarction, electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia), 
bradycardia, and concurrent use of more than one QTc interval-prolonging drug. Other risk 
factors include sepsis and increases in plasma concentrations of QTc interval-prolonging drugs 
due to rapid intravenous infusion, pharmacokinetic interactions, and inadequate dose adjustment 
of renally cleared or hepatically metabolized QTc interval prolonging drugs in patients with 
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kidney or liver disease, respectively.3,18,19 Risk factors are important with respect to the 
development of QTc interval prolongation and the occurrence of TdP. In comparison with 
patients with no risk factors, the odds ratio (OR) for QTc interval prolongation in patients with 1 
risk factor is 3.2 (95% confidence interval [CI] 2.1-5.5). The OR for QTc interval prolongation 
increases substantially in patients with 2 risk factors (7.3, 95% CI 4.6-11.7) and  3 or more risk 
factors (9.2, 95% CI 4.9-17.4).20 In an analysis of 144 published journal articles describing 249 
patients who experienced TdP induced by noncardiovascular drugs, nearly 100% had at least one 
risk factor, while 71% of the patients had  at least 2 risk factors.21 TdP in the absence of risk 
factors is exceedingly rare.   
 The field of predictive analytics endeavors to generate predictions about the future 
using a variety of techniques including data mining, modeling, machine learning, and others.22 In 
view of the importance of risk factors for the development of QTc interval prolongation and TdP, 
methods of risk stratification and awareness of magnitude of risk may be valuable for reducing 
the likelihood of a potentially catastrophic arrhythmia. A number of investigators have 
developed methods for risk quantification and prediction of the development of QTc interval 
prolongation and/or TdP. In addition, some investigators have incorporated predictive analytics 
into clinical decision support (CDS) tools for the purpose of alerting clinicians regarding patients 
at increased risk of developing QTc interval prolongation. The objectives of this paper are to 
review the effectiveness of predictive analytics for identification of patients at risk of drug-
induced QTc interval prolongation and discuss the efficacy of incorporation of predictive 
analytics into CDS tools in clinical practice. 
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Methods 
A systematic review of the literature was performed according to the preferred reporting items 
for systematic reviews and meta-analyses (PRISMA) statement.23 MEDLINE (1879-December 
2017), the Cochrane database (1966- December 2017), EMBASE (1991- December 2017), and 
OVID (1946 – 2017) were reviewed for English-language articles using the search terms “QTc 
interval prolongation OR QT interval prolongation OR Torsades de pointes AND risk score 
AND QT risk score OR genetic variant risk score AND decision support AND QT alert system 
OR QT alert.” Our PRISMA flow diagram is presented in Figure 1. A total of 10 studies were 
included in the final qualitative synthesis.  
 
Predictive Analytics for Assessing Risk of QTc Interval Prolongation 
A QTc interval risk score, named the pro-QTc score, was developed by investigators at the Mayo 
Clinic.24 Over a period of seven months, 86,107 ECGs were performed in 52,579 patients. The 
investigators collected data retrospectively from medical records on clinical diagnoses, abnormal 
laboratory values, and drugs known to prolong the QTc interval, and summarized these data in 
the pro-QTc score. Rather than assigning weights to individual components of the score, each 
factor was considered equipotent and assigned a score of 1. Components of the pro-QTc score 
are presented in Table 1. The investigators reported that 99% of 470 patients with QTc interval ≥ 
500 ms had at least one risk factor (excluding female sex). The mean (± standard deviation [SD]) 
pro-QTc score in patients with QTc interval ≥ 500 ms was 3.1 ± 1.6; after exclusion of 45 
patients with congenital LQTS, the mean pro-QTc score in patients with QTc interval ≥ 500 ms 
was 3.2 ± 1.7. Medications were the greatest contributors to the pro-QTc score (score-proportion 
37%), followed by QT interval-prolonging diagnosis (23%) and electrolyte abnormalities (22%). 
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A pro-QTc score of ≥ 4 predicted mortality (hazard ratio [HR] 1.72, 95% CI 1.11-2.66, p<0.001). 
The number of QTc interval-prolonging medications and electrolyte abnormalities were the only 
components of the score that were significantly associated with death; female sex and number of 
QTc interval-prolonging diagnoses were not. Mortality was better predicted using the pro-QTc 
score including electrolyte abnormalities and QTc interval-prolonging medications only in a 
multivariate analysis together with age, serum creatinine, QRS duration and cardiovascular 
admission diagnosis, compared with using a pro-QTc score that included female sex and 
diagnoses/conditions known to be associated with QTc interval prolongation (HR 1.26, 95% CI 
1.10-1.44).  Limitations of this analysis include the retrospective design and the absence of 
weighting of components of the risk score. In addition, sensitivity, specificity, and positive and 
negative predictive values of the pro-QTc score for prediction of mortality were not reported.  
Our research group sought to quantify the risk of drug-induced QTc interval prolongation 
through development and validation of a QTc interval prolongation risk score.19 In a prospective, 
observational study, we collected data from 1200 patients admitted to two 28-bed cardiac ICUs 
in a tertiary care academic medical center. Initially, we developed a QTc interval prolongation 
risk score model in 900 consecutive patients admitted to these units. Using logistic regression 
analysis, we identified independent risk factors for QTc interval prolongation, defined as a QTc 
interval > 500 ms or an increase of ≥ 60 ms from admitting value occurring at any time during 
the hospitalization. We determined ORs with 95% CI for the independent risk factors, and 
assigned to each independent variable a weighted point score (1, 2, or 3) based on the log OR 
(Table 2). Risk scores were categorized as low, moderate, or high based on predictive accuracy 
using the C-score from receiver operating characteristics curves. Risk scores of < 7, 7-10, and > 
11 were categorized as “low,” moderate,” and “high” risk, respectively. The resulting risk score 
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was then validated in an additional population of 300 patients admitted to these units. The 
predictive performance of the QTc interval risk score was good with respect to sensitivity, 
specificity, and positive and negative predictive value (Table 3). Limitations of this study include 
the fact that the investigation was conducted at a single institution in two nearly identical cardiac 
ICUs; the results may not apply to patients in general medical units or other areas where QTc 
interval-prolonging drugs may be used (such as cancer centers, ambulatory care clinics, and 
methadone clinics). In addition, our analysis was based on a relatively small sample of patients. 
  Another risk score for QTc interval prolongation, called RISQ-PATH, was developed in 
hospitalized patients receiving haloperidol or a QTc interval-prolonging antibiotic/antimycotic in 
an academic tertiary care medical center in Belgium.25 In this prospective observational study, 
patients underwent a baseline ECG prior to the administration of the QTc interval-prolonging 
medication and a follow-up ECG at the time of expected steady state plasma concentration 
(between 3 and 11 days after initiation of therapy). The investigators collected demographic, 
disease-related, and laboratory data from the medical record. Points were allocated to risk factors 
for QTc interval prolongation previously identified in the literature, based on the investigators’ 
assessment of the strength of the evidence: 6 points for strong evidence, 3 points for moderate 
evidence, and 1 point for low evidence. QTc interval-prolonging drugs were scored based on the 
QT drugs list on the CredibleMeds.org10 website: known risk = 3 points, possible risk = 0.5 
points, conditional risk = 0.25 points. The maximum value in the RISQ-PATH score was 40.5 
plus the sum of the scores for QTc interval-prolonging drugs. The investigators reported that 26 
of 178 (14.6%) patients developed QTc interval prolongation, of which 25 had a RISQ-PATH 
score > 10. A RISQ-PATH score < 10 demonstrated good sensitivity and negative predictive 
value for predicting QTc interval prolongation (Table 3). However, the specificity and positive 
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predictive value of the score were low, likely as a result of the strategy of allocation of points 
based on assessment of strength of literature evidence. The QT drugs list at CredibleMeds.org is 
based on assessment of whether QTc interval-prolonging drugs are known to be associated with 
TdP, or whether there is a possible or conditional risk of TdP.10 However, drugs within any given 
category may lengthen QTc interval by substantially different degrees, which may have 
influenced the specificity and predictive accuracy of this score. Another limitation is that the 
investigators included risk variables in the score for which there is minimal evidence of an 
independent association with QTc interval prolongation or TdP, such as cigarette smoking, body 
mass index of 30 kg/m2 or more, C-reactive protein greater than 5 mg/mL, and hypertension.  
Strauss and colleagues developed the first genetic risk score for drug-induced QTc 
interval prolongation and TdP.26 The investigators hypothesized that response to one or multiple 
QTc interval-prolonging drugs can be predicted by a weighted combination of common genetic 
variants identified by genome-wide association studies. Healthy subjects (n=22) were enrolled in 
a double-blind, placebo-controlled, crossover trial and randomized to one of four QTc interval-
prolonging drugs (dofetilide, quinidine, ranolazine, and verapamil hydrochloride) or placebo. 
Verapamil data were not included in the final analysis as the dose administered did not prolong 
the QTc interval in the study subjects. A washout period of 7 days between each drug 
administration was observed and triplicate 10-second ECG measurements were collected at 15 
specific time points over the course of 24 hours.  
The genetic risk score was calculated based on a pool of 61 common variants that were 
shown to influence the QTc interval in subjects of European or African descent.27 While some of 
these were variants known to be associated with congenital LQTS genes, others were variants in 
genes encoding proteins that were not previously known to influence cardiac repolarization. 
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Investigators assigned a weight to each allele based on the observed Fridericia-corrected QTc 
interval effect and multiplied that by its frequency in the population. The sum of the weighted 
QTc effect of each allele resulted in an individual genetic QTc score ranging from 0 to 122. This 
genetic score described 27% of the variability (p=0.03) in pre-treatment QTc intervals among 
subjects of European descent. The risk score significantly described 30% of the variability in 
QTc interval response to dofetilide (r=0.55, 95% CI 0.09-0.81, p=0.02) and 27% of the QTc 
interval response variability to ranolazine (r=0.52, 95% 0.05-0.80, p=0.03). The risk score was 
not able to significantly describe the QTc interval response variability (23%) to quinidine 
(r=0.48, 95% CI -0.03-0.79, p=0.06).   
Among subjects of African descent (n=4), it was difficult to precisely determine the 
degree of QTc interval variability that was explained by the genetic risk score due to the small 
sample size. Despite this, the genetic risk score was significantly associated with baseline QTc 
intervals (p=0.03) in this population. A significant correlation was also established between the 
baseline QTc interval and response to dofetilide, but not quinidine or ranolazine, among the 
African subjects. Some of the limitations of this analysis were a small study sample, particularly 
among subjects of African descent and the lack of inclusion of subjects of other races. In 
addition, the study only enrolled healthy volunteers; the predictive accuracy of the genetic risk 
score in patients with cardiovascular comorbidities or other risk factors exposed to chronic 
treatment with QTc interval-prolonging drugs remains to be determined.  
The investigators subsequently tested their genetic risk score in an independent  
population of 216 patients who had experienced TdP to predict the risk of drug-induced TdP 
compared with 771 controls.26 The genetic risk score significantly predicted risk of drug-induced 
TdP (r=12%, p=1x10-7). This study represents the first example of a genetic risk score being used 
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as an analytical predictive tool to determine degree of response to drug-induced QTc interval 
prolongation and to predict the occurrence of TdP.  
Incorporation of Predictive Analytics into Clinical Decision Support Tools 
 
A number of investigators have incorporated predictive analytics into CDS tools, which have 
been tested for their ability to alert clinicians regarding patients who are at risk for QTc interval 
prolongation or who already have QTc interval prolongation. We incorporated our validated QTc 
interval prolongation risk score into a CDS computer alert, and tested this alert to assess its 
effectiveness for reducing the risk of QTc interval prolongation in the cardiac ICUs at Indiana 
University Health Methodist Hospital in Indianapolis, Indiana.28 With the assistance of 
information technology specialists, we developed and implemented a CDS computer alert using 
information extracted from patients’ electronic medical records. When a drug known to be 
associated with TdP was prescribed to a patient with moderate or high risk of QTc interval 
prolongation as designated by application of our QTc interval risk score, a computer alert 
appeared on the screen to the pharmacist entering the order. A computer alert did not appear for 
patients prescribed a torsadogenic drug for which the risk of QTc interval prolongation was 
designated low risk by our risk score. Therefore, when the CDS alert appeared, the pharmacist 
(and prescribers contacted by the pharmacist) knew that the alert was appearing only to patients 
at a certain level of risk. The CDS computer alert also described the risk factors present that 
contributed to the risk score in each patient. When an alert appeared for a patient at moderate or 
high risk of QTc interval prolongation, the pharmacist contacted the prescriber to discuss, as 
appropriate for each specific patient, the need for electrolyte replacement, more intensive QTc 
interval monitoring, and whether alternative, non-QTc interval-prolonging drug therapy could be 
substituted to minimize the risk. We then determined the risk of QTc interval prolongation 
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(defined as a QTc interval > 500 ms or an increase of > 60 ms from the admitting value 
occurring at any time during the hospitalization) over a one-year prior to (n=1200) and eight 
months following (n=1200) implementation of the CDS computer alert in our cardiac ICUs.  
Implementation of the CDS computer alert significantly reduced the adjusted odds ratio 
for QTc interval prolongation (OR 0.65, 95% CI 0.56-0.89, p<0.0001). Implementation of the 
CDS computer alert did not significantly influence the prescribing of QTc interval-prolonging 
drugs (OR 0.87, 95% CI 0.77-1.23, p=0.13). However, implementation of the CDS computer 
alert significantly reduced the prescribing of noncardiovascular QTc interval-prolonging drugs 
(OR 0.79, 95% CI 0.63-0.91, p<0.03). After implementation of the CDS computer alert, there 
were 470 alert triggers, of which 82% were overridden for a variety of reasons. Therefore, 
implementation of a risk–quantified CDS computer alert did not completely eliminate “alert 
fatigue,” although an 82% override rate is lower than the 93-96% alert override rate reported in 
hospitalized patients.29 Despite the override rate, implementation of this CDS computer alert 
significantly reduced the odds of QTc interval prolongation in these cardiac ICUs and 
significantly reduced prescribing of noncardiovascular QTc interval-prolonging drugs. 
Limitations of this analysis include the fact that the analysis was “pre-post,” which can introduce 
temporal bias. A randomized, parallel group study of implementation of this CDS computer alert 
versus usual care would be valuable. Since the completion of this research, Indiana University 
Health has implemented this CDS computer alert at most of its institutions across the state of 
Indiana. 
At the Mayo Clinic, an institution-wide computer-based QTc interval alert system has 
been developed and implemented.24  This alert system screens all ECGs performed and applies an 
automated algorithm to determine whether an ECG displays marked QTc interval prolongation. 
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The algorithm initially excludes ECGs exhibiting atrial fibrillation or flutter. An automated QTc 
interval alert is sent to providers for adult patients with QRS duration < 120 ms, a QTc interval ≥ 
500 ms, and a heart rate ≤ 100 beats per minutes (bpm) and for those with QRS duration ≥ 120 
ms, a QTc interval ≥ 550 ms, and a heart rate ≤ 100 bpm. An automated QTc interval alert is sent 
to providers for pediatric patients with QRS duration < 120 ms, a QTc interval  ≥ 470 ms, and a 
heart rate ≤ 150 bpm and for those with a QRS duration ≥ 120 ms, a QTc interval ≥ 550 ms, and 
a heart rate ≤ 150 bpm. The Mayo Clinic QTc interval alert was sent for 2% of patients, of whom 
41% had no other identifiable reason for QTc interval prolongation (such as a functioning 
ventricular pacemaker). In contrast to the CDS alert developed by our group, which is designed 
to alert clinicians when patients are at moderate to high risk of developing QTc interval 
prolongation so that steps can be taken to prevent QTc interval prolongation, the Mayo Clinic 
CDS alert is designed to notify providers when patients have developed QTc interval 
prolongation. However, implementation of the Mayo Clinic CDS alert resulted in a significant 
reduction in the proportion of completed orders for QTc interval-prolonging drugs per ordering 
attempt (94% vs 77%, , p<0.001), which resulted in a 13.9% decrease in administration of QTc 
interval-prolonging medications to patients.30 In addition, implementation of the Mayo Clinic 
CDS alert for QTc interval prolongation resulted in significant increases in frequency of ECG 
monitoring and acknowledgement of the issue of QTc interval prolongation in the electronic 
health record.31 
In a follow-up study, the Mayo Clinic investigators utilized their institution-wide QTc 
interval alert system to assess the prevalence of QTc interval prolongation in pediatric patients 
and determine the causes.32 Over a period of 8 months, 1303 pediatric ECGs were performed, 
and 68 children (5%) had QTc interval prolongation. The average pro-QTc score in children with 
A
cc
ep
te
d 
A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
QTc prolongation was 1.4 ±0.8. Over 50% of the pediatric population with QTc interval 
prolongation had congenital LQTS, which was not unexpected as the Mayo Clinic is a major 
referral center for such patients. In patients without congenital LQTS, the most common cause of 
QTc interval prolongation was administration of QTc interval-prolonging drugs, followed by 
comorbidities and electrolyte abnormalities. The QT alert system utilized in this study in a 
pediatric population was proven to be clinically useful for two reasons. First, it identified a child 
with previously undiagnosed congenital LQTS. Second, it singled out potentially modifiable 
factors that were causing QTc prolongation in a pediatric population. Utilization of the QTc 
interval alert system resulted in relevant changes in the prescribing practices of QTc interval-
prolonging medications; prescribers changed approximately 80% of the QTc interval-prolonging 
medications after they received the QTc interval alert.32  
In another follow-up investigation, the Mayo Clinic investigators utilized their QTc 
interval prolongation alert system to determine the prevalence of QTc interval prolongation 
among 7522 adult patients who were admitted to the emergency department (ED) and who had  
at least one 12-lead ECG associated with their ED visit.33 The QTc alert was activated 
(indicating QTc interval prolongation) in 93 (1.2%) patients. The mean pro-QT score of subjects 
with QTc interval prolongation was 3.0 ± 1.6. The majority of the ED patients (64%) had more 
than one condition associated with QTc interval prolongation, the most common of which was 
receiving at least one QTc interval-prolonging drug (77%). Mortality at 30 days was significantly 
higher in ED patients identified by the QTc interval alert than in those who did not have QTc 
interval prolongation (13% vs 3.7%, p<0.001). In addition, as in the study in the pediatric 
population, the Mayo Clinic alert enabled the diagnosis of a patient with previously undiagnosed 
congenital LQTS.  
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Summary and Conclusions 
 
QTc interval prolongation occurs commonly, particularly in hospitalized patients, who tend to 
have a larger number of risk factors. Risk factors are important for the development of QTc 
interval prolongation and TdP, which are much more likely to occur when patients have one or 
more risk factors. Risk scores for QTc interval prolongation have been developed in patients 
from various patient populations including those in cardiac ICUs and in broader populations of 
hospitalized or health system patients. One group developed a risk score that includes 
information regarding genetic polymorphisms; this risk score significantly predicted the 
occurrence of TdP. Future research is required to determine the value of developing a risk score 
that combines genetic information with other known risk factors for QTc interval prolongation. 
CDS tools have been developed to alert clinicians when patients are at moderate or high risk for 
developing QTc interval prolongation or to alert clinicians when patients have already developed 
QTc interval prolongation. Implementation of these CDS approaches has been shown to reduce 
the risk of QTc interval prolongation in cardiac ICUs and identify patients at increased risk for 
mortality so that interventions can be taken to modify the risk. Development and implementation 
of CDS alerts for QTc interval prolongation require time and resources. While these CDS alerts 
for QTc interval prolongation have been shown to modify the risk of this ECG abnormality, the 
impact of these CDS systems on overall patient safety outcomes, such as TdP and sudden cardiac 
death, relative to the cost of development and implementation requires further study. 
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Table 1. Diagnoses/Conditions Included in the Pro-QTc Risk Score24 
Acute coronary syndrome (≤7 days) 
 
Anorexia nervosa or starvation 
 
Bradycardia (heart rate < 45 beats/minute) 
 
Heart failure (left ventricular ejection fraction < 40%) 
 
Diabetes mellitus (types 1 and 2) 
 
Female sex 
 
Hypertrophic cardiomyopathy 
 
Hypoglycemia (documented and in the absence of diabetes) 
 
Intoxication with QT interval-prolonging drugs (≥ 24 hours) 
 
Long QT syndrome 
 
Pheochromocytoma 
 
Kidney dialysis 
 
Status after conversion of atrial fibrillation to sinus rhythm (7 days after cardioversion, 
radiofrequency ablation or the Maze procedure) 
Status after cardiac arrest (24 hours) 
 
Status after syncope or seizure (24 hours) 
 
Stroke, subarachnoid hemorrhage, head trauma (≤ 7 days) 
 
Electrolyte disturbances 
Hypocalcemia (calcium <  4.65 mg/dL) 
Hypokalemia (potassium < 3.6 mmol/L) 
Hypomagnesemia (magnesium < 1.7 mg/dL) 
 
≥1 QTc interval-prolonging medication from CredibleMeds®10 within previous 7 days  
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Table 2. Components of Risk Score for QTc Interval Prolongation (adapted with permission 
from reference 19) 
Risk Factors         Points 
 
Age > 68 years        1 
Female         1 
Loop diuretic         1 
Serum K+ < 3.5 mEq/L       2 
Admitting QTc interval > 450 ms      2 
Acute myocardial infarction       2 
Sepsis          3 
Heart failure with reduced ejection fraction      3 
1 QTc interval-prolonging drug      3a 
≥ 2 QTc interval-prolonging drugs      3a 
Maximum score        21 
aIf a patient is receiving ≥ 2 QTc interval-prolonging drugs he/she is assigned a total score of 6; 3 
points for receiving 1 QTc interval prolonging drugs and 3 points for receiving > 2 QTc interval-
prolonging drugs.  
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Table 3. Comparison of Published Predictive Analytics Tools to Predict Risk of or Identify 
Patients with QTc Interval Prolongation 
 Mayo pro-QTc 
score24 
Tisdale et al risk 
score19 
RISQ-PATH score25 
Study design Retrospective Prospective 
observational 
Prospective observational 
Study setting Mayo Clinic Cardiac ICU Tertiary care center 
Study patients 
(n) 
52,570 900 development, 
300 validation 
178 
QTc interval 
prolongation 
definition 
> 500 ms > 500 ms or increase 
≥ 60 ms from 
baseline  
≥ 450(males) 
≥ 470(females) 
QTc interval 
prolongation 
prevalence  
1145/52,570 (2%) 274/900 (30.4%) 26/178 (14.6%) 
Mortality in 
patients with 
QTc interval 
prolongation 
20% N/A N/A 
Risk score 
factors 
weighted 
No - 1 point per risk 
factor 
Yes - 1-3 points per 
risk factor 
Yes - 0.5-6 points per risk 
factor 
Validation No Yes No 
Sensitivity NA 74%a, 67%b 96.2% (95% CI 78.4-
99.8%) 
Specificity NA 77% a, 88%b 32.9% (25.6-41.0%) 
Positive 
predictive 
value 
NA 79%a, 55%b 19.7% (13.4-27.9%) 
Negative 
predictive 
value 
NA 76%a, 88%b 98% (88.2-99.9%) 
Identifies 
patients at high 
risk of QTc 
interval 
prolongation, 
before 
developing it 
No Yes Yes 
Predicts 
patients at 
highest risk of 
Yes No No 
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mortality 
CI = confidence interval; ICU = intensive care unit; NA = not applicable. 
aHigh risk.  
bModerate risk. 
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Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow 
diagram. 
 
 
  
